BioAge Labs, Inc.

48 Days Left

Offering Date:
stock pursuant and/or traceable to BioAge’s registration statement for the initial public offering held on or about September 26, 2024.

Lead Plaintiff Deadline:
March 10, 2025

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.

First Name

Last Name

Phone

Street Address

City

State

Zip

Shares Purchased

Purchase Date

Estimated Loss

The submission of this form does not create an attorney-client relationship.

Allegations

According to the complaint, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 trial for azelaprag, its lead product candidate, citing safety concerns over elevated liver transaminase levels in participants. This came as a surprise because, at the time of its IPO less than three months earlier, BioAge highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs. Following this news, BioAge’s stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of BioAge purchased or acquired during the class period listed above and/or pursuant to the stock offering(s) referenced above.

Lead Plaintiff Deadline

If you suffered a loss in BioAge during the relevant time frame or pursuant to the relevant offering(s), you have until March 10, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.